Agilent Technologies, Inc.
NYSE:AMedical - Diagnostics & Research
+$3.04 today
- Market cap
- $50.00B
- Beta
- 1.26
- P/E (TTM)
- 25.5
- EPS (TTM)
- $5.00
- Dividend yield
- 0.59%
Volume 2.48M
Average 2.24M
A Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
Agilent Technologies, Inc.NYSE: A
Investing Cash Flow · Q3 FY2026 · quarter ended Jul 2026
Investing cash flow growth accelerates
Q3 FY2026 investing cash flow of $1.03B (cash outflow) rose 975.0% year over year, ahead of the +2.7% change in trailing-twelve-month investing cash flow. Sequentially, it rose 1240.3% from the prior quarter. Over 3 fiscal years it compounded at +5.2% a year.
Context
- Investing cash flow amounted to 5.7% of revenue in FY2025, down 13.7 pp from a year earlier.
- Investing cash flow grew in size in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +975.0% holds above the trailing-twelve-month pace of +2.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Investing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (394M) USD
- Year-over-year change
- +68.7%
| Period | Period end | Investing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-10-31 | (394M) | +68.7% |
| FY2024 | 2024-10-31 | (1.26B) | -305.8% |
| FY2023 | 2023-10-31 | (310M) | +8.3% |
| FY2022 | 2022-10-31 | (338M) | +54.9% |
| FY2021 | 2021-10-31 | (749M) | — |
Investing Cash Flow vs competitors
How A compares with its peers on the latest reported figures
- A's LTM Jul 2026 investing cash flow of $1.29B is the 3rd largest of the 9 companies compared; the peer median is $204.85M.
- Its year-over-year change of +2.7% is the 7th highest of 9, against a peer median of +36.0%.
- Investing cash flow amounts to 17.5% of revenue for A, versus a peer median of 6.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $11.08B | +635.7% | -18.8% | 43.3% | |
| LTM Sep 2026 | $7.98B | +62.3% | +23.3% | 16.9% | |
| LTM Jul 2026 | $1.29B | +2.7% | +5.2% | 17.5% | |
| LTM Jun 2026 | $242.15M | +51.6% | -25.1% | 11.5% | |
| LTM Jun 2026 | $237.1M | +19.3% | -46.0% | 9.2% | |
| LTM Jun 2026 | $172.61M | +20.5% | +11.6% | 4.2% | |
| LTM Jun 2026 | $144.3M | -41.2% | -7.9% | 4.1% | |
| LTM Jul 2026 | $83.26M | -112.7% | -49.3% | 2.9% | |
| LTM Jul 2026 | $29.35M | +118.0% | +12.1% | 0.6% | |
| Peer median (excluding A) | $204.85M | +36.0% | -13.4% | 6.7% | |
Competitors are the stored peer set for A. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Oct 2021 | FY2022 Oct 2022 | FY2023 Oct 2023 | FY2024 Oct 2024 | FY2025 Oct 2025 |
|---|---|---|---|---|---|
| Net Income | 1.21B | 1.25B | 1.24B | 1.29B | 434M |
| Depreciation & Amortization | 321M | 317M | 271M | 257M | 288M |
| Deferred Income Tax | 14M | 8M | (56M) | (64M) | (130M) |
| Stock-Based Compensation | 110M | 125M | 111M | 129M | 128M |
| Change in Working Capital | (102M) | (478M) | (116M) | 83M | (58M) |
| Accounts Receivables | (128M) | (321M) | 132M | 7M | (149M) |
| Inventory | (136M) | (248M) | (33M) | 34M | 45M |
| Accounts Payables | 64M | 121M | (171M) | 103M | 16M |
| Other Working Capital | 98M | (30M) | (44M) | (61M) | 30M |
| Other Non-Cash Items | (68M) | 86M | 322M | 57M | 897M |
| Operating Cash Flow | 1.49B | 1.31B | 1.77B | 1.75B | 1.56B |
| Capital Expenditures | (189M) | (291M) | (298M) | (378M) | (407M) |
| Acquisitions (Net) | (546M) | (52M) | (1M) | (862M) | 4M |
| Purchases of Investments | (22M) | (13M) | (8M) | (5M) | 0 |
| Sales of Investments | 12M | 22M | 5M | 0 | 8M |
| Other Investing Activities | (4M) | (4M) | (8M) | (13M) | (199M) |
| Investing Cash Flow | (749M) | (338M) | (310M) | (1.26B) | (394M) |
| Debt Repayment | 356M | 26M | (35M) | 637M | (41M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 72M |
| Common Stock Repurchased | (788M) | (1.14B) | (575M) | (1.15B) | (425M) |
| Dividends Paid | (236M) | (250M) | (265M) | (274M) | (282M) |
| Other Financing Activities | (28M) | 58M | (55M) | 35M | (39M) |
| Financing Cash Flow | (696M) | (1.37B) | (930M) | (752M) | (715M) |
| Effect of Forex Changes | 3M | (36M) | 5M | (2M) | 9M |
| Net Change in Cash | 43M | (434M) | 537M | (261M) | 459M |
| Free Cash Flow | 1.3B | 1.02B | 1.47B | 1.37B | 1.15B |
Agilent Technologies, Inc.
NYSE:A
Intrinsic Alpha fair value
Locked
Current Price
$177.33
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.